Aesthetic approvals top Healio Dermatology FDA news in 2023

Key takeaways:

• The most read FDA approval of 2023 was Restylane Eyelight for the treatment of under eye hallows.
• This list includes the approvals of Ycanth and Litfulo, first-ever approved treatments for their indications.

The FDA approved multiple products for dermatologic indications this year.

Aesthetics approvals such as Restylane Eyelight for undereye hollows and Tixel for periorbital wrinkles were among the most read articles on Healio Dermatology in 2023.

Here are five of the most read FDA approvals of 2023:

FDA approves Restylane Eyelight for undereye hollows

In June, the FDA approved Restylane Eyelight, an undereye hyaluronic acid dermal filler, for the treatment of undereye hollows in adults aged 21 years and older. Restylane Eyelight is the first U.S. product formulated with non-animal stabilized hyaluronic acid technology for volume loss under the eyes. Read more.

FDA approves Tixel noninvasive skin resurfacing technology to treat periorbital wrinkles

Tixel, an innovative noninvasive skin resurfacing technology indicated for periorbital wrinkle treatment, was approved in August. Tixel works by delivering short bursts of thermal energy into the skin’s surface without damaging the deeper tissues. Read more.

FDA approves Ycanth as first molluscum contagiosum treatment

Over the summer, the FDA approved Ycanth topical solution for the treatment of the viral skin infection molluscum contagiosum in patients aged as young as 2 years, making it the first-ever approved treatment for this disease in the U.S. Made from cantharidin 0.7%, this treatment became available in September 2023. Read more.

FDA approves Sculptra for cheek wrinkles

The FDA approved Sculptra, an injectable poly-L-lactic acid, for the correction of cheek wrinkles, in April 2023. Sculptra injectable poly-L-lactic acid (PLLA) was first approved in 2004 for the correction of facial lipoatrophy and facial wrinkles. According to the recent approval, Sculptra maintains improvement for up to 2 years. Read more.

Litfulo becomes first FDA-approved treatment for adolescents with severe alopecia

In June, Litfulo (ritlecitinib) became the first FDA-approved treatment for severe alopecia in patients aged as young as 12 years. Litfulo is a selective dual Janus kinase 3 and tyrosine family kinase inhibitor that can be taken orally once a day. Read more.